Skip to content


  • Review
  • Open Access

Multiple sclerosis: an example of pathogenic viral interaction?

Virology Journal201714:42

  • Received: 9 November 2016
  • Accepted: 25 February 2017
  • Published:


A hypothesis is formulated on viral interaction between HHV-6A and EBV as a pathogenic mechanism in Multiple Sclerosis (MS). Evidence of molecular and genetic mechanisms suggests a link between HHV-6A infection and EBV activation in the brain of MS patients leading to intrathecal B-cell transformation. Consequent T-cell immune response against the EBV-infected cells is postulated as a pathogenic basis for inflammatory lesion formation in the brain of susceptible individuals. A further link between HHV-6A and EBV involves their induction of expression of the human endogenous retrovirus HERV-K18-encoded superantigen. Such virally induced T-cell responses might secondarily also lead to local autoimmune phenomena. Finally, research recommendations are formulated for substantiating the hypothesis on several levels: epidemiologically, genetically, and viral expression in the brain.


  • Multiple Sclerosis
  • HHV-6A
  • EBV
  • EBNA-2
  • LMP1
  • MHC2TA
  • RBPJ-kappa
  • Syncytin-1
  • HERV-K18


The role of viral interactions in pathogenesis has been reported for several human diseases. Examples are coinfection with HCV and HIV [1] or other hepatitis viruses [2] as well as with HIV and HHV-6 [3] or HHV-7 [4].

For a long time a viral aetiology of Multiple Sclerosis (MS) has been suspected und discussed. Evidence for it has often been circumstantial and sometimes not reproducible. However, in the past 20 to 30 years the importance of two viruses for MS has stood the test of time and recent reviews have summarized the evidence for their aetiological role in MS – Human Herpes Virus 6A (HHV-6A) [5] and Epstein Barr Virus (EBV) [6, 7]. The hypothesis on a viral interaction between HHV-6A and EBV as a pathogenic mechanism in multiple sclerosis (MS) has first been formulated by the author in 2004 [8]. However, a possible connection between the two herpes viruses has not been further studied in detail so far. Here, it will be argued that that the involvement of two different herpes viruses in MS is not circumstantial but fundamental to the aetio-pathogenetic processes in MS. This view could partly explain why two highly prevalent viruses are causing a relatively rare disease. First, some of the pertinent evidence for the involvement of the two viruses in MS will be summarized, and then the pieces of the puzzles will be put together in sight of new evidence supporting the picture.


An important fact is that all evidence relating MS to HHV-6 involves HHV-6A but not HHV-6B, two quite different herpes viruses [9]. Leibovitch & Jacobson (2014) have recently reviewed the role of HHV-6A in MS [5].

The basic concept is that HHV-6A is a neurotropic virus infecting the astrocytes of MS-patients [10]. The active replication of HHV-6A in MS patients correlates with a polymorphism of MHC2TA (rs4774C) [11], a gene that has been associated with MS [12]. MHC2TA is coding for the MHC class II transactivator (CIITA) which plays an essential role in the expression of MHC class II molecules by astrocytes [13]. MHC class II molecules are essential for presentation of antigens to CD4-T-cells, although IFN-γ is needed as an additional factor to enable astrocytes to do so [14, 15]. There seems also to be a combined effect of IFN-γ and HHV-6A infection on astrocytes resulting in the upregulation of ICSBP (IRF8) in astrocytes [16], a gene that has been associated with MS [17]. The HHV-6A replication related MHC2TA rs4774 minor allele (C) seems to diminish the expression of MHC class II molecules and therefore might allow the immune escape of the virus, similarly as described for CMV in an astrocytoma cell line [18]. Nevertheless, oligoclonal IgG from MS patients, specific for the HHV-6-A major capsid proteins have been demonstrated [19], indicating that viral immune escape is not absolute.


The role of EBV in MS has recently been reviewed by Pender (2011) [6] and Owens & Bennett (2012) [7]. Here, the basic concept is that B-cells in the brain of MS-patients are EBV-transformed, and that the cellular immune response towards the EBV-infected cells is the hallmark of the inflammatory basis of MS. Intrathecal CD8 T-cells of MS patients recognizing lytic Epstein-Barr virus proteins have been described recently [20, 21].

Indirect evidence for transformation of B-cells in the CNS of MS patients comes from early observations that the pattern of oligoclonal bands in the CSF of MS patients is stable over time [22]. This patient-specific antibody “fingerprint” has recently been analysed at the level of epitope specificities that stayed identical over several years [23]. A systemic examination of the specificities of such antibodies produced by B-cells in the CNS of MS patients revealed no MS-specific pattern [24]. One explanation for these findings would be that such specificities are random as one would expect from EBV-transformed and immortalized B-cells [25].

EBV persistence has been described in post-mortem brain tissue of MS patients and viral reactivation has been localized to acute lesions and ectopic B-cell follicles in the meninges [26]. Notably, EBNA2+ and LMP1+ cells were detected in perivascular inflammatory cell infiltrates in active white matter lesions. However, others could not reproduce such direct evidence of EBV infection in brains of MS patients and the issue still is controversial (reviewed in [27]). On the other hand, oligoclonal IgG from MS patients, specific for the EBV proteins BRRF2 and EBNA-1 could be demonstrated [28, 29].

The link

Disease-modifying therapies in MS

Support for a combined pathogenic role of HHV-6A and EBV in MS might come from studies involving disease-modifying therapies. In fact, the first trial in MS with specific anti-herpes virus treatment showed that acyclovir might inhibit the triggering of MS [48]. Later, the introduction of IFN-β as the first disease modifying therapy of MS was initially based on the assumption that the anti-viral effect of IFN-β is the basis of its treatment effect. Particularly, an interference with EBV and MSRV is suspected. However, the exact mode of its action is not yet fully understood (for review see [49]). Apart from EBV and MSRV, IFN-β treatment seems to affect HHV-6 expression. Patients that fail to suppress HHV-6 during IFN-β treatment have been demonstrated to also show a poor clinical response [50].

Another line of evidence supporting the pathogenic role of HHV-6A and EBV in MS comes from the treatment effect of B-cell depletion. Originally, chimeric monoclonal antibodies against the pan-B cell marker CD20, in form of rituximab, were used to successfully treat EBV-related post-transplant lymphoproliferative disorders (PTLD) [51]. The idea of B-cell depletion with rituximab was then successfully adopted to treatment of relapsing-remitting MS [52]. Even better results were later achieved by using the fully humanized anti-CD20 monoclonal antibody ocrelizumab (OCR) that showed to be effective not only in relapsing-remitting MS but also in primary progressive MS [53], illustrating the central role of B-cells in the pathogenesis of MS.

The third line of evidence comes from treatment with the α4 integrin (VLA-4) antagonist natalizumab. Treatment with natalizumab carries the risk of provoking progressive multifocal leukoencephalopathy (PML) caused by latent JC virus in the CNS (for review see [54]). However, in addition HHV-6 seems to be reactivated in the CNS of some natalizumab treated patients [55].

None of the above-mentioned disease-modifying therapies in MS directly prove the postulated interaction of HHV-6A and EBV, but all of them are well in line with infection of both HHV-6A and EBV in the brain of MS patients.


A link is postulated between HHV-6A and EBV in the aetio-pathogenesis of MS.

In summary, the tenet is that infection with the neurotropic HHV-6A leads to transformation of latently EBV-infected B-cells in the CNS. Both viruses will elicit a T-cell response, either specific towards HHV-6A and EBV, or non-specific as a response to the HERV-K18-encoded superantigen. Such viral induced T-cell responses might secondarily also lead to autoimmune phenomena. Evidence for mechanisms for induction of autoimmunity by viral infections has recently been reviewed [56].

The hypothesis could be tested on several levels:
  • Epidemiological level: The prevalence of genetic subtypes of EBV (EBNA2) and HHV-6A and its subtypes are not known. Establishing the prevalence of co-infection with the two viruses is crucial to estimate the likelihood of their combined effects in MS.

  • Level of genetic associations to MS: The relations between MHC2TA as well as EBNA2 polymorphisms with MS suggest a link between active replication of HHV-6A, regulated by MHC2TA, and HHV-6A-induced EBNA2 expression in EBV-infected cells. A crucial test would be to look for genetic interaction between all three polymorphisms, MHC2TA, EBNA2, and HERV-K18 in the risk for MS.

  • Molecular level: Both, findings for HHV-6A and EBV expression in MS lesions are not unanimous. Studies looking for co-expression of the two viruses in brain tissue of MS patients using the MALDI-TOF MS technology [57] and/or multiplex detection of herpes viruses in CSF by PCR [58] might clarify the issue.



Tegument protein BRRF2


Cytomegalo virus


Central nervous system


Cerebrospinal fluid


Epstein Barr Nuclear Antigen 2


Epstein Barr Virus


Hepatitis Virus C


Human endogenous retrovirus


Human Herpes Virus – 6A


Human Immunodeficiency Virus


Interferon Consensus Sequence-Binding Protein, Interferon Regulatory Factor 8


Interferon beta


Interferon gamma


Latent Membrane Protein 1


Matrix Assisted Laser Desorption Ionization — Time of Flight Mass Spectrometry


Major Histocompatibility Complex, Transactivator Gene


Multiple Sclerosis


Multiple sclerosis retrovirus


Polymerase chain reaction


Recombination Signal-Binding Protein J kappa



Not applicable.


Not applicable.

Availability of data and materials

Not applicable.

Author’s contributions

The author is the corresponding and only author.

Competing interest

The author declares that he has no competing interests.

Consent for publication

Not applicable.

Ethics approval and consent to participate

Not applicable.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

labormedizinisches zentrum Dr Risch, Landstr. 157, 9494 Schaan, Fürstentum, Liechtenstein


  1. Winnock M, Salmon-Céron D, Dabis F, Chêne G. Interaction between HIV-1 and HCV infections: towards a new entity? J Antimicrob Chemother. 2004;53:936–46. doi:10.1093/jac/dkh200.View ArticlePubMedGoogle Scholar
  2. Lin L, Verslype C, van Pelt JF, van Ranst M, Fevery J. Viral interaction and clinical implications of coinfection of hepatitis C virus with other hepatitis viruses. Eur J Gastroenterol Hepatol. 2006;18:1311–9. doi:10.1097/01.meg.0000243881.09820.09.View ArticlePubMedGoogle Scholar
  3. Grivel JC, Ito Y, Fagà G, Santoro F, Shaheen F, Malnati MS, et al. Suppression of CCR5- but not CXCR4-tropic HIV-1 in lymphoid tissue by human herpesvirus 6. Nat Med. 2001;7:1232–5. doi:10.1038/nm1101-1232.View ArticlePubMedGoogle Scholar
  4. Lisco A, Grivel J-C, Biancotto A, Vanpouille C, Origgi F, Malnati MS, et al. Viral interactions in human lymphoid tissue: Human herpesvirus 7 suppresses the replication of CCR5-tropic human immunodeficiency virus type 1 via CD4 modulation. J Virol. 2007;81:708–17. doi:10.1128/JVI.01367-06.View ArticlePubMedGoogle Scholar
  5. Leibovitch EC, Jacobson S. Evidence linking HHV-6 with multiple sclerosis: an update. Curr Opin Virol. 2014;9:127–33. doi:10.1016/j.coviro.2014.09.016.View ArticlePubMedGoogle Scholar
  6. Pender MP. The essential role of Epstein-Barr virus in the pathogenesis of multiple sclerosis. Neuroscientist. 2011;17:351–67. doi:10.1177/1073858410381531.View ArticlePubMedPubMed CentralGoogle Scholar
  7. Owens GP, Bennett JL. Trigger, pathogen, or bystander: the complex nexus linking Epstein- Barr virus and multiple sclerosis. Mult Scler. 2012;18:1204–8. doi:10.1177/1352458512448109.View ArticlePubMedPubMed CentralGoogle Scholar
  8. Fierz W. Virale Hypothese der Multiplen Sklerose. In: Kesselring J, editor. Multiple Sklerose. 4th ed. Stuttgart: Kohlhammer-Verlag; 2004.Google Scholar
  9. Ablashi D, Agut H, Alvarez-Lafuente R, Clark DA, Dewhurst S, DiLuca D, et al. Classification of HHV-6A and HHV-6B as distinct viruses. Arch Virol. 2014;159:863–70. doi:10.1007/s00705-013-1902-5.View ArticlePubMedGoogle Scholar
  10. Donati D, Martinelli E, Cassiani-ingoni R, Ahlqvist J, Hou J, Major EO, et al. Variant-specific tropism of human herpesvirus 6 in human astrocytes. J Virol. 2005;79:9439–48. doi:10.1128/JVI.79.15.9439.View ArticlePubMedPubMed CentralGoogle Scholar
  11. Alvarez-Lafuente R, Martinez A, Garcia-Montojo M, Mas A, De Las Heras V, Dominguez-Mozo MI, et al. MHC2TA rs4774C and HHV-6A active replication in multiple sclerosis patients. Eur J Neurol. 2010;17:129–35. doi:10.1111/j.1468-1331.2009.02758.x.View ArticlePubMedGoogle Scholar
  12. Bronson PG, Caillier S, Ramsay PP, McCauley JL, Zuvich RL, De Jager PL, et al. CIITA variation in the presence of HLA-DRB1*1501 increases risk for multiple sclerosis. Hum Mol Genet. 2010;19:2331–40. doi:10.1093/hmg/ddq101.View ArticlePubMedPubMed CentralGoogle Scholar
  13. Dong Y, Benveniste EN. Immune function of astrocytes. Glia. 2001;36:180–90. doi:10.1002/glia.1107.View ArticlePubMedGoogle Scholar
  14. Fierz W, Endler B, Reske K, Wekerle H, Fontana A. Astrocytes as antigen-presenting cells. I. Induction of Ia antigen expression on astrocytes by T cells via immune interferon and its effect on antigen presentation. J Immunol. 1985;134:3785–93.PubMedGoogle Scholar
  15. Barcia C, Mitxitorena I, Carrillo-de Sauvage MA, Gallego J-M, Pérez-Vallés A. Imaging the microanatomy of astrocyte-T-cell interactions in immune-mediated inflammation. Front Cell Neurosci. 2013;7:58. doi:10.3389/fncel.2013.00058.View ArticlePubMedPubMed CentralGoogle Scholar
  16. Meeuwsen S, Persoon-Deen C, Bsibsi M, Bajramovic JJ, Ravid R, De Bolle L, et al. Modulation of the cytokine network in human adult astrocytes by human herpesvirus-6A. J Neuroimmunol. 2005;164:37–47. doi:10.1016/j.jneuroim.2005.03.013.View ArticlePubMedGoogle Scholar
  17. De Jager PL, Jia X, Wang J, de Bakker PIW, Ottoboni L, Aggarwal NT, et al. Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nat Genet. 2009;41:776–82. doi:10.1038/ng.401.View ArticlePubMedPubMed CentralGoogle Scholar
  18. Le Roy E, Mühlethaler-Mottet A, Davrinche C, Mach B, Davignon JL. Escape of human cytomegalovirus from HLA-DR-restricted CD4(+) T-cell response is mediated by repression of gamma interferon-induced class II transactivator expression. J Virol. 1999;73:6582–9.PubMedPubMed CentralGoogle Scholar
  19. Alenda R, Álvarez-Lafuente R, Costa-Frossard L, Arroyo R, Mirete S, Álvarez-Cermeño JC, et al. Identification of the major HHV-6 antigen recognized by cerebrospinal fluid IgG in multiple sclerosis. Eur J Neurol. 2014;21:1096–101. doi:10.1111/ene.12435.View ArticlePubMedGoogle Scholar
  20. Lossius A, Johansen JN, Vartdal F, Robins H, Benth JŠ, Holmøy T, et al. High-throughput sequencing of TCR repertoires in multiple sclerosis reveals intrathecal enrichment of EBV-reactive CD8(+) T cells. Eur J Immunol. 2014;44:3439–52. doi:10.1002/eji.201444662.View ArticlePubMedGoogle Scholar
  21. Van Nierop GP, et al. Intrathecal CD8 T-cells of multiple sclerosis patients recognize lytic Epstein-Barr virus proteins. Multiple Sclerosis J. 2015. doi:10.1177/1352458515588581.Google Scholar
  22. Petzold A. Intrathecal oligoclonal IgG synthesis in multiple sclerosis. J Neuroimmunol. 2013;262:1–10. doi:10.1016/j.jneuroim.2013.06.014.View ArticlePubMedGoogle Scholar
  23. Yu X, Burgoon M, Green M, Barmina O, Dennison K, Pointon T, et al. Intrathecally synthesized IgG in multiple sclerosis cerebrospinal fluid recognizes identical epitopes over time. J Neuroimmunol. 2011;240–241:129–36.View ArticlePubMedPubMed CentralGoogle Scholar
  24. Willis SN, Stathopoulos P, Chastre A, Compton SD, Hafler DA, O’Connor KC. Investigating the antigen specificity of multiple sclerosis central nervous system-derived immunoglobulins. Front Immunol. 2015;6:600.View ArticlePubMedPubMed CentralGoogle Scholar
  25. Tosato G, Blaese RM, Yarchoan R. Relationship between immunoglobulin production and immortalization by Epstein Barr virus. J Immunol. 1985;135:959–64.PubMedGoogle Scholar
  26. Serafini B, Rosicarelli B, Franciotta D, Magliozzi R, Reynolds R, Cinque P, et al. Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. J Exp Med. 2007;204:2899–912. doi:10.1084/jem.20071030.View ArticlePubMedPubMed CentralGoogle Scholar
  27. Lassmann H, Niedobitek G, Aloisi F, Middeldorp JM. Epstein-Barr virus in the multiple sclerosis brain: a controversial issue--report on a focused workshop held in the Centre for Brain Research of the Medical University of Vienna, Austria. Brain. 2011;134:2772–86. doi:10.1093/brain/awr197.View ArticlePubMedPubMed CentralGoogle Scholar
  28. Cepok S, Zhou D, Srivastava R, Nessler S, Stei S, Büssow K, et al. Identification of Epstein-Barr virus proteins as putative targets of the immune response in multiple sclerosis. J Clin Invest. 2005;115:1352–60. doi:10.1172/JCI200523661.1352.View ArticlePubMedPubMed CentralGoogle Scholar
  29. Pfuhl C, Oechtering J, Rasche L, Gieß RM, Behrens JR, Wakonig K, et al. Association of serum Epstein–Barr nuclear antigen-1 antibodies and intrathecal immunoglobulin synthesis in early multiple sclerosis. J Neuroimmunol. 2015;285:156–60. doi:10.1016/j.jneuroim.2015.06.012.View ArticlePubMedGoogle Scholar
  30. Flamand L, Stefanescu I, Ablashi DV, Menezes J. Activation of the Epstein-Barr virus replicative cycle by human herpesvirus 6. J Virol. 1993;67:6768–77.PubMedPubMed CentralGoogle Scholar
  31. Cuomo L, Angeloni A, Zompetta C, Cirone M, Calogero A, Frati L, et al. Human herpesvirus 6 variant A, but not variant B, infects EBV-positive B lymphoid cells, activating the latent EBV genome through a BZLF-1-dependent mechanism. AIDS Res Hum Retroviruses. 1995;11:1241–5. doi:10.1089/aid.1995.11.1241.View ArticlePubMedGoogle Scholar
  32. Cuomo L, Trivedi P, De Grazia U, Calogero A, D’Onofrio M, Yang W, et al. Upregulation of Epstein-Barr virus-encoded latent membrane protein by human herpesvirus 6 superinfection of EBV-carrying Burkitt lymphoma cells. J Med Virol. 1998;55:219–26. doi:10.1002/(SICI)1096-9071(199807)55:3<219::AID-JMV7>3.0.CO;2-4.View ArticlePubMedGoogle Scholar
  33. Mechelli R, Manzari C, Policano C, Annese A, Picardi E, Umeton R, et al. Epstein-Barr virus genetic variants are associated with multiple sclerosis. Neurology. 2015;84(13):1362–8. doi:10.1212/WNL.0000000000001420.View ArticlePubMedPubMed CentralGoogle Scholar
  34. Juryńczyk M, Selmaj K. Notch: a new player in MS mechanisms. J Neuroimmunol. 2010;218:3–11. doi:10.1016/j.jneuroim.2009.08.010.View ArticlePubMedGoogle Scholar
  35. Henkel T, Ling PD, Hayward SD, Peterson MG. Mediation of Epstein-Barr virus EBNA2 transactivation by recombination signal-binding protein J kappa. Science. 1994;265:92–5. doi:10.1126/science.8016657.View ArticlePubMedGoogle Scholar
  36. Zhao B, Zou J, Wang H, Johannsen E, Peng C-W, Quackenbush J, et al. Epstein-Barr virus exploits intrinsic B-lymphocyte transcription programs to achieve immortal cell growth. Proc Natl Acad Sci U S A. 2011;108:14902–7. doi:10.1073/pnas.1108892108.View ArticlePubMedPubMed CentralGoogle Scholar
  37. Querol L, Clark PL, Bailey MA, Cotsapas C, Cross AH, Hafler DA, et al. Protein array-based profiling of CSF identifies RBPJ as an autoantigen in multiple sclerosis. Neurology. 2013;81:956–63. doi:10.1212/WNL.0b013e3182a43b48.View ArticlePubMedPubMed CentralGoogle Scholar
  38. Liu H, Zheng H, Li M, Hu D, Tang M, Cao Y. Upregulated expression of kappa light chain by Epstein-Barr virus encoded latent membrane protein 1 in nasopharyngeal carcinoma cells via NF-kappaB and AP-1 pathways. Cell Signal. 2007;19:419–27. doi:10.1016/j.cellsig.2006.07.012.View ArticlePubMedGoogle Scholar
  39. Rinker JR, Trinkaus K, Cross AH. Elevated CSF free kappa light chains correlate with disability prognosis in multiple sclerosis. Neurology. 2006;67:1288–90. doi:10.1212/01.wnl.0000238107.31364.21.View ArticlePubMedGoogle Scholar
  40. Presslauer S, Milosavljevic D, Huebl W, Aboulenein-Djamshidian F, Krugluger W, Deisenhammer F, et al. Validation of kappa free light chains as a diagnostic biomarker in multiple sclerosis and clinically isolated syndrome: a multicenter study. Mult Scler J. 2015;online before print:1–9. doi:10.1177/1352458515594044.Google Scholar
  41. Mameli G, Poddighe L, Mei A, Uleri E, Sotgiu S, Serra C, et al. Expression and activation by Epstein Barr virus of human endogenous retroviruses-W in blood cells and astrocytes: inference for multiple sclerosis. PLoS One. 2012;7, e44991. doi:10.1371/journal.pone.0044991.View ArticlePubMedPubMed CentralGoogle Scholar
  42. Antony JM, Deslauriers AM, Bhat RK, Ellestad KK, Power C. Human endogenous retroviruses and multiple sclerosis: innocent bystanders or disease determinants? Biochim Biophys Acta. 1812;2011:162–76. doi:10.1016/j.bbadis.2010.07.016.Google Scholar
  43. Sutkowski N, Conrad B, Thorley-Lawson DA, Huber BT. Epstein-Barr virus transactivates the human endogenous retrovirus HERV- K18 that encodes a superantigen. Immunity. 2001;15:579–89.View ArticlePubMedGoogle Scholar
  44. Tai AK, Luka J, Ablashi D, Huber BT. HHV-6A infection induces expression of HERV-K18-encoded superantigen. J Clin Virol. 2009;46(1):47–8. doi:10.1016/j.jcv.2009.05.019.View ArticlePubMedGoogle Scholar
  45. Tai AK, O’Reilly EJ, Alroy KA, Simon KC, Munger KL, Huber BT, et al. Human endogenous retrovirus-K18 Env as a risk factor in multiple sclerosis. Mult Scler. 2008;14:1175–80. doi:10.1177/1352458508094641.View ArticlePubMedPubMed CentralGoogle Scholar
  46. Sutkowski N, Palkama T, Ciurli C, Sekaly RP, Thorley-Lawson DA, Huber BT. An Epstein-Barr virus-associated superantigen. J Exp Med. 1996;184:971–80.View ArticlePubMedGoogle Scholar
  47. Hong J, et al. A Common TCR V-D-J Sequence in Vβ13.1 T Cells Recognizing an Immunodominant Peptide of Myelin Basic Protein in Multiple Sclerosis. J Immunol. 1999;163:3530.PubMedGoogle Scholar
  48. Lycke J, Svennerholm B, Hjelmquist E, et al. Acyclovir treatment of relapsing-remitting multiple sclerosis. A randomized, placebo-controlled, double-blind study. J Neurol. 1996;243:214–24.View ArticlePubMedGoogle Scholar
  49. Annibali V, Mechelli R, Romano S, et al. IFN-β and multiple sclerosis: From etiology to therapy and back. Cytokine Growth Factor Rev. 2015;26:221–8.View ArticlePubMedGoogle Scholar
  50. Garcia-Montojo M, De Las Heras V, Dominguez-Mozo M, et al. Human herpesvirus 6 and effectiveness of interferon beta 1b in multiple sclerosis patients. Eur J Neurol. 2011;18:1027–35. doi:10.1111/j.1468-1331.2011.03410.x.View ArticlePubMedGoogle Scholar
  51. Ganne V, Siddiqi N, Kamaplath B, et al. Humanized anti-CD20 monoclonal antibody (Rituximab) treatment for post-transplant lymphoproliferative disorder. Clin Transplant. 2003;17:417–22.View ArticlePubMedGoogle Scholar
  52. Hauser SL, Waubant E, Arnold DL, et al. B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis. N Engl J Med. 2008;358:676–88. doi:10.1056/NEJMoa0706383.View ArticlePubMedGoogle Scholar
  53. Montalban X, Hemmer B, Rammohan K, et al. Efficacy and Safety of Ocrelizumab in Primary Progressive Multiple Sclerosis: Results of the Phase III Double-Blind, Placebo-Controlled ORATORIO Study (S49.001). Neurology. 2016;86:S49.001.Google Scholar
  54. Warnke C, Menge T, Hartung H-P, Racke MK, Cravens PD, Bennett JL, et al. Natalizumab and progressive multifocal leukoencephalopathy. Arch Neurol. 2010;67:923–30.View ArticlePubMedPubMed CentralGoogle Scholar
  55. Yao K, Gagnon S, Akhyani N, Williams E, Fotheringham J, Frohman E, et al. Reactivation of human herpesvirus-6 in natalizumab treated multiple sclerosis patients. PLoS One. 2008;3, e2028.View ArticlePubMedPubMed CentralGoogle Scholar
  56. Sfriso P, Ghirardello A, Botsios C, Tonon M, Zen M, Bassi N, et al. Infections and autoimmunity: the multifaceted relationship. J Leukoc Biol. 2010;87:385–95.View ArticlePubMedGoogle Scholar
  57. Sjöholm MIL, Dillner J, Carlson J. Multiplex detection of human herpesviruses from archival specimens by using matrix-assisted laser desorption ionization-time of flight mass spectrometry. J Clin Microbiol. 2008;46:540–5. doi:10.1128/JCM.01565-07.View ArticlePubMedGoogle Scholar
  58. Yamamoto T, Nakamura Y. A single tube PCR assay for simultaneous amplification of HSV-1/-2, VZV, CMV, HHV-6A/-6B, and EBV DNAs in cerebrospinal fluid from patients with virus-related neurological diseases. J Neurovirol. 2000;6:410–7. doi:10.3109/13550280009018305.View ArticlePubMedGoogle Scholar


© The Author(s). 2017